IDH1 and cancer: IDH enzymes normally produce α-ketoglutarate (αKG), however, cancer cells with mutated IDH1/2 produce 2-hydroxyglutarate (2-HG) which is detrimental to TET2, because TET2 uses αKG as a co-activator, resulting in TET2 having impaired functionality [95].